| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3316326 | Pancreatology | 2016 | 4 Pages |
Abstract
Pancreatic volume decreases statistically significantly under treatment with both the multi-tyrosine kinase inhibitor Sorafenib and the angiogenesis inhibitor Bevacizumab. This volume reduction is most likely due to a reduced microvasculation by inhibition of VEGF.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Veit Phillip, Tina Zahel, Klaus Bärtl, Sebastian Rasch, Oliver Ebert, Roland M. Schmid, Ernst Rummeny, Hana Algül,